scholarly article | Q13442814 |
P356 | DOI | 10.1093/AJE/KWP466 |
P8608 | Fatcat ID | release_o5t5peen2fe3pbdvbvsk2gkcue |
P698 | PubMed publication ID | 20231211 |
P50 | author | Jacco Wallinga | Q30105749 |
Veerle M. Coupé | Q73190157 | ||
Chris J L M Meijer | Q90379336 | ||
P2093 | author name string | Johannes Berkhof | |
Johannes A Bogaards | |||
Maria Xiridou | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 817-825 | |
P577 | publication date | 2010-03-15 | |
P1433 | published in | American Journal of Epidemiology | Q4744243 |
P1476 | title | Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus | |
P478 | volume | 171 |
Q36106799 | A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization |
Q39604503 | Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention |
Q40301885 | Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus. |
Q35661925 | Bayesian time-series analysis of a repeated-measures poisson outcome with excess zeroes |
Q39122093 | Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions |
Q36843345 | Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial |
Q58085060 | Capturing sexual contact patterns in modelling the spread of sexually transmitted infections: Evidence using Natsal-3 |
Q38599579 | Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study |
Q35596183 | Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis |
Q92089108 | Estimated impact of human papillomavirus vaccines on infection burden: The effect of structural assumptions |
Q45765408 | Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach |
Q35463790 | Genital transmission of human papillomavirus in recently formed heterosexual couples |
Q93054025 | Gini coefficients for measuring the distribution of sexually transmitted infections among individuals with different levels of sexual activity |
Q40170982 | Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands |
Q41753413 | High-risk human papillomavirus in Galicia, Spain: prevalence and evaluation of the sample representativeness. |
Q34462627 | Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study |
Q47603242 | Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). |
Q34979497 | Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach |
Q51731914 | Impacts of human papillomavirus vaccination for different populations: A modelling study. |
Q34490267 | Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach |
Q38673360 | Mechanistic mathematical models: An underused platform for HPV research |
Q41933591 | Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution |
Q47612436 | Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland |
Q64091049 | Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines |
Q51103584 | Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. |
Q36319941 | Optimizing technology for cervical cancer screening in high-resource settings |
Q35166924 | Papillomaviruses: Viral evolution, cancer and evolutionary medicine |
Q36597805 | Partner Human Papillomavirus Viral Load and Incident Human Papillomavirus Detection in Heterosexual Couples |
Q38002182 | Prevalence and genotype distribution of cervical human papillomavirus infection among female sex workers in Asia: a systematic literature review and meta-analysis. |
Q41611517 | Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? |
Q34113476 | Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models |
Q37016576 | The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care |
Q21296754 | The Strong Protective Effect of Circumcision against Cancer of the Penis |
Q34583160 | The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models |
Q39704260 | The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands |
Q101116336 | The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment |
Q35038766 | The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model |
Q37439328 | Type-specific human papillomavirus biological features: validated model-based estimates |
Q36979148 | Updating the natural history of human papillomavirus and anogenital cancers |
Q51773606 | Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer. |
Search more.